Apollo Therapeutics Funding: $260M Raised, Series C (2023)
Apollo Therapeutics is a Biotech company based in Cambridge, UK. It has raised $260M in total funding. Latest round: Series C.
Apollo Therapeutics funding overview
Apollo Therapeutics is a Biotech company based in Cambridge, UK. Apollo Therapeutics has raised $260M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series C announced in December 2023. The round record for Apollo Therapeutics runs through 2023; nothing later has been disclosed. Investors on record include Patient Square Capital, M&G plc, Rock Springs Capital. 3 distinct backers are named across the disclosed rounds.
Apollo Therapeutics at a glance
Total raised
$260M
Latest round
Series C
Latest round date
December 2023
Industry
Biotech
Headquarters
Cambridge, UK
Notable investors
Patient Square Capital, M&G plc, Rock Springs Capital
Frequently asked about Apollo Therapeutics funding
How much has Apollo Therapeutics raised?
Apollo Therapeutics has raised $260M in total disclosed funding across the rounds on record.
Who has invested in Apollo Therapeutics?
Patient Square Capital, M&G plc, Rock Springs Capital are named among the investors backing Apollo Therapeutics.
What was the latest Apollo Therapeutics funding round?
The most recent disclosed round is a Series C, announced in December 2023.
Where is Apollo Therapeutics based?
Apollo Therapeutics is based in Cambridge, UK.
What sector does Apollo Therapeutics operate in?
Apollo Therapeutics is tracked under Biotech from Cambridge, UK, with $260M in disclosed funding.
When did Apollo Therapeutics last raise?
The last disclosed Apollo Therapeutics round closed in December 2023 at Series C.
Every Apollo Therapeutics figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare Biotech companies in Cambridge at a similar stage.
